Found 2 clinical trials
HER2-PREDICT: Translational Study of Tumor Samples From DS8201-A-U301 and DS8201-A-U302 Trials.
Patients who will participate, are participating or have participated in Daichi Sankyo INC sponsored Ds8201-A-U301 and Ds8201-A-U302 trials will be asked to participate to HER2-PREDICT study offering them a new informed consent. In order to identify mRNA ERBB2 levels, we will evaluate by gene expression tumor samples from these patients.
- 0 views
- 19 Feb, 2024
A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer
The primary objective of this study is to evaluate the safety and tolerability of H3B-6545 and palbociclib when administered in combination in order to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of this combination in women with advanced or metastatic estrogen receptor-positive (ER+) HER2- …
- 0 views
- 19 Feb, 2024